Rhumbline Advisers Trims Position in The Cooper Companies, Inc. (NASDAQ:COO)

Rhumbline Advisers lowered its position in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 0.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 354,900 shares of the medical device company's stock after selling 2,951 shares during the period. Rhumbline Advisers owned approximately 0.18% of Cooper Companies worth $32,626,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Ashton Thomas Securities LLC purchased a new position in shares of Cooper Companies during the 3rd quarter valued at about $25,000. Byrne Asset Management LLC acquired a new stake in Cooper Companies during the fourth quarter worth about $33,000. Covestor Ltd raised its position in Cooper Companies by 144.9% during the third quarter. Covestor Ltd now owns 338 shares of the medical device company's stock valued at $37,000 after acquiring an additional 200 shares in the last quarter. Brown Brothers Harriman & Co. lifted its holdings in Cooper Companies by 191.0% in the third quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company's stock valued at $46,000 after acquiring an additional 275 shares during the period. Finally, West Financial Advisors LLC purchased a new stake in Cooper Companies in the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 24.39% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the company an "overweight" rating in a report on Friday, December 6th. Morgan Stanley cut their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an "equal weight" rating for the company in a report on Friday, December 6th. Needham & Company LLC reissued a "hold" rating on shares of Cooper Companies in a research note on Friday, December 6th. StockNews.com lowered Cooper Companies from a "buy" rating to a "hold" rating in a research note on Wednesday, December 11th. Finally, Citigroup reduced their price target on Cooper Companies from $116.00 to $115.00 and set a "buy" rating for the company in a report on Friday, December 6th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $117.00.

Cooper Companies Price Performance

Shares of Cooper Companies stock traded down $0.21 during mid-day trading on Friday, reaching $88.48. 1,564,854 shares of the stock traded hands, compared to its average volume of 1,455,233. The stock has a market capitalization of $17.66 billion, a PE ratio of 45.37, a PEG ratio of 2.19 and a beta of 1.00. The business has a 50-day moving average of $93.07 and a 200 day moving average of $99.57. The Cooper Companies, Inc. has a fifty-two week low of $84.76 and a fifty-two week high of $112.38. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.00 by $0.04. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the prior year, the company earned $0.87 EPS. The firm's revenue was up 9.8% compared to the same quarter last year. On average, analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.